Journal of Clinical & Experimental Cardiology · 2017 · 21 citations · 63 references
MedicineCardiologyOncologyCardio-oncologyChemotherapyEarly DetectionAnthracycline CardiotoxicityBiomarkers In Cardio-oncologyCancer BiomarkersCancer Therapy-related CardiotoxicityCardiac AssessmentCardiac BiomarkersBiomarkers Of Anthracycline CardiotoxicityCardiac Monitoring During Cancer TherapyCardiotoxicityChemotherapy-related ToxicityEarly Detection Of CardiotoxicityEchocardiographic BiomarkersSerum BiomarkersTroponin Elevation
Cardiotoxicity is an important issue for breast cancer patients receiving anthracycline-trastuzumab therapy in the adjuvant setting. Studies show that 3-36% of patients receiving anthracyclines and/or trastuzumab experience chemotherapy related cardiac dysfunction (CRCD) and approximately 17% of patients must stop chemotherapy due to the consequences of CRCD. There is currently no standardized, clinically verified way to detect CRCD early, but common practices include serial echocardiography and troponin measurements, which can be timely, costly, and not always available in areas where health care resources are scarce. Furthermore, detection of CRCD, before there is any echocardiographic evidence of dysfunction or clinical symptoms present, would allow maximal benefit of chemotherapy and minimize cardiac complications. Creating a panel of serum biomarkers would allow for more specificity and sensitivity in the early detection of CRCD, which would be easy to implement and cost effective in places with limited health care. Based on a review of the literature, we propose creating a biomarker panel consisting of topoisomerase 2β, serum troponin T/I, myeloperoxidase, NT-proBNP, miR-208b, miR-34a, and miR-150 in breast cancer patients receiving anthracyclines and/or trastuzumab to detect CRCD before any signs of overt cardiotoxicity are apparent.
63
The MicroRNA Spectrum in 12 Body Fluids
Jessica A. Weber, David Baxter, Shile Zhang et al. · Clinical Chemistry · 2010 · 2.7K citations · Full text
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang, Xiaobing Liu, Tasneem Bawa‐Khalfe et al. · Nature Medicine · 2012 · 1.9K citations
Medicine, Biochemistry, Pharmacology +14
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Andrew D. Seidman, Clifford A. Hudis, Mary Kathryn Pierri et al. · Journal of Clinical Oncology · 2002 · 1.5K citations
Medicine, Cardiology, Oncology +16